Aurion Makes Leadership Announcements

Aurion Biotech announced the appointments of Edward J. Holland, MD, as Chief Medical Officer, and Eris P. Jordan, OD, as Chief Development Officer.

Aurion is developing AURN001, an investigational, single-administration, allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial disease.

Dr. Holland has been a key supporter of Aurion since its inception, serving as Chair of the Medical Advisory Board and leading the first team of U.S. corneal surgeons to deliver the cell therapy developed by Aurion, based on foundational technology from Professor Shigeru Kinoshita at Kyoto Prefecture University of Medicine.

Dr. Jordan, a co-founder of Aurion, has been instrumental at every stage of the company’s clinical journey. She led the foundational clinical trials in El Salvador, including the IOTA and ESCALON studies, and has since overseen the expansion of Aurion’s clinical development program into North America. 

“Joining Aurion in this capacity is both exciting and deeply meaningful. I’ve seen firsthand the transformative potential of AURN001, and I look forward to helping the team bring this therapy to patients who urgently need new options," Dr. Holland said.

“This program has always been about patients—those we’ve met and those still waiting. I’m grateful to lead the development of AURN001, and to work alongside a team so deeply committed to scientific excellence and to the people we serve," Dr. Jordan said.